Full Press Release Details
Therapeutics Announces Pricing of Offering
& Vancouver, British Columbia - May 31, 2026 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT)
("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform
cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an
offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from
the offering, before deducting placement agent's fees and other offering expenses, are expected to be approximately $4.7 million.
The offering is expected to close on June 2, 2026, subject to satisfaction of customary closing conditions. The Company is relying upon
the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain
transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement
of business objectives.
is acting as sole placement agent for the offering.
securities described above are being offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No.
333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on January 22,
2024 and declared effective on January 31, 2024. The offering is being made only by means of a written prospectus. A final prospectus
supplement and accompanying prospectus relating to the offering will be filed with the SEC and can be accessed for free on the SEC's
website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained,
when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
BriaCell Therapeutics Corp.
is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information
is available at https://briacell.com/.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading
"Risk Factors" in the Company's most recent Annual Report on Form 10-K, and under "Risks and Uncertainties"
in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission,
all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking
statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)
accepts responsibility for the adequacy or accuracy of this release.